Akorn, Inc. Announces Contract Manufacturing Supply Agreement with X-Gen Pharmaceuticals

Buffalo Grove, IL - Akorn, Inc. today announced that it has signed a commercial manufacturing supply agreement with X-Gen Pharmaceuticals for the product, Neomycin and Polymyxin B Sulfates Solution for Irrigation USP.

X-Gen's Neomycin and Polymyxin B Sulfates Solution for Irrigation USP was recently approved as an Abbreviated New Drug Application (ANDA) by the United States Food and Drug Administration (FDA). Akorn's Decatur, IL manufacturing facility, with capabilities to produce sterile injectables, ophthalmics, and lyophilized pharmaceuticals, is the approved manufacturing site for this product. This event represents another new product approval received for the Decatur, IL manufacturing facility.

Arthur S. Przybyl, Akorn's President and Chief Executive Officer stated, "Our contract product development and manufacturing business segment is an exciting growth area for the company. Akorn is pleased to be a strategic partner with X-Gen in the manufacturing of this product."

X-Gen President and CEO Susan Badia points out that the introduction of Neomycin and Polymyxin B Sulfates Solution for Irrigation USP will effectively provide the marketplace with a generic competitor to Neosporin(R) G.U. Irrigant(1). "The addition of this product to our offering is another example of X-Gen's long standing tradition and commitment to provide affordable drug therapy options to the healthcare community. We are pleased to have a manufacturing partnership with Akorn as we continue serving the healthcare community as a preferred source for generic choices, including Neomycin and Polymyxin B Sulfates Solution for Irrigation USP."

SOURCE: Akorn, Inc.